A Phase 3 Study of Tanezumab for Chronic Low Back Pain

NCT02528253 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1832

Enrollment

INDUSTRY

Sponsor class

Conditions

Low Back Pain

Interventions

BIOLOGICAL: Placebo to Week 16; tanezumab 5mg SC
BIOLOGICAL: Placebo to Week 16, tanezumab 10 mg SC
BIOLOGICAL: Tanezumab 5 mg SC
BIOLOGICAL: Tanezumab 10 mg SC
BIOLOGICAL: Tramadol PR oral

Sponsor

Pfizer

Collaborators

[object Object]